View printer-friendly version
<< Back
CytomX Announces Management Team Promotions

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2015 – CytomX, a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced the promotion of several members of its leadership team.

Debanjan Ray, who previously served as vice president of business development and alliance management, has been promoted to senior vice president of corporate development and strategy. Prior to joining CytomX, Mr. Ray held positions as the vice president of business development at Itero Biopharmaceuticals and as associate director of business development at Portola Pharmaceuticals.

Bryan Irving, Ph.D., who previously served as senior director of cancer immunology, has been promoted to vice president of cancer immunology. Prior to joining CytomX, Dr. Irving conducted research at Genentech that resulted in the anti-PD-L1 antibody, atezolizumab, currently in clinical development, and held positions in academia where he conducted influential research into the single-chain chimeric antigen receptor (CAR) technology now being used in patients’ T cells to treat hematologic malignancies.

Jon Terrett, Ph.D., who previously served as senior director of oncology, has been promoted to vice president of oncology discovery. Prior to joining CytomX, Dr. Terrett was chief scientific officer of Oxford BioTherapeutics and served as a director for each of Medarex, CellTech and Oxford GlycoSciences.

Carol Talkington Verser, Ph.D., who previously served as senior director of intellectual property, has been promoted to vice president of intellectual property. Prior to joining CytomX, Dr. Verser held positions as executive vice president, intellectual property and business development, at Heska Corporation and as patent agent and technical specialist at Sheridan Ross.

“We are committed to the development and advancement of our team at every level and these senior promotions are illustrative of our commitment to building a great company around great people,” said Sean McCarthy, D.Phil, chief executive officer of CytomX. “I look forward to continuing to work closely with Debanjan, Bryan, Carol and Jon as we continue to pursue our vision of transforming lives with safer, more effective therapies.”